Reem Jan Farid
Cairo University, Egypt
At present assistant Professor in Clinical pathology (Specialization: Immunology), Department of Clinical Pathology, Faculty of Medicine, Cairo university, Egypt.M.B.B.Ch (Excellent with Honours) adn Masters in Clinical and Chemical Pathology. Techniques Mastered are Interpretation of Variety of PCR polymerase chain reaction techniques, FISH florescence in situ hybridization, Cell culture( for stem cell research and others),Flow cytometry,BM aspirate and biopsy Technique and interpretation,Immunehistochemistry and Tests for diagnosis of immunodeficiency diseases.
Background and Objectives: Mesenchymal stem cells (MSCs) of bone origin provide a supportive micro-environmental niche for hematopoietic stem cells. We aimed to isolate and characterize MSCs derived from bone marrow (BM) of untreated chronic myeloid leukemia (CML) patients, and to determine the presence of the BCR-ABL fusion gene in such MSCs, as well as their potential to support hematopoietic stem cells (HSCs) in order to evaluate the safety and eff ectiveness in autologous transplantation. Materials and Methods: Diagnostic BM samples of CML patients (n=12) were cultured to isolate MSCs. Cells were characterized by flow cytometry and differentiation potential. Detection of Philadelphia chromosome was done by real time polymerase chain reaction, fluorescent in situ hybridization and karyotyping. Their supportive potential for HSCs was assessed by their coculture with umbilical cord blood mononuclear cells.Results: CML MSCs expressed typical MSCs phenotype by flowcytometry, had osteogenic and adipogenic differentiation ability. CML MSCs don't harbor the Philadelphia chromosome and could support in vitro cord blood expansion.Conclusion: MSCs are devoid of BCR-ABL fusion gene and are able to support hematopoietic stem cells hence they could be used as co-transplantation in stem cell therapy for CML.